Levofloxacin induced bullous fixed drug eruption: a rare case report.

continuing diabetes mellitus drug misuse drug-related side effects and adverse reactions education education department hospital pharmacy

Journal

European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294

Informations de publication

Date de publication:
03 2022
Historique:
received: 20 10 2020
revised: 18 11 2020
accepted: 01 12 2020
pubmed: 24 12 2020
medline: 2 4 2022
entrez: 23 12 2020
Statut: ppublish

Résumé

A 42-year-old male patient visited the outpatient department for follow-up with a history of respiratory tract infection and diabetes mellitus. His main symptom was peeling of his epidermal layer of skin, and bullous fixed drug eruption on the lower and upper limbs and bank region of the body. Following assessment, the patient was prescribed levothyroxine, hydroxychloroquine, levofloxacin, and a combination of sulfamethoxazole-trimethoprim. On assessing causality of the adverse drug reaction (ADR), different ADR assessment scales such as the WHO-UMC Scale, Naranjo Scale, and Hartwig's Severity Assessment Scale were used, and the ADR was found by these scales to be 'likely', 'moderate', and 'probable', respectively. It was found that ADRs such as bullous fixed drug eruptions are not fatal but can cause patient anxiety and a reduced quality of life. This case report will help physicians and clinicians to become aware and vigilant about the ADR caused by levofloxacin, facilitating its early detection and management.

Identifiants

pubmed: 33355292
pii: ejhpharm-2020-002566
doi: 10.1136/ejhpharm-2020-002566
pmc: PMC8899637
doi:

Substances chimiques

Levofloxacin 6GNT3Y5LMF

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e95-e96

Informations de copyright

© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Clin Diagn Res. 2014 Oct;8(10):HC01-3
pubmed: 25478366
Lancet. 2017 Oct 28;390(10106):1996-2011
pubmed: 28476287
CA Cancer J Clin. 1980 May-Jun;30(3):143-57
pubmed: 6769553
Lancet. 1998 Apr 18;351(9110):1183
pubmed: 9643702

Auteurs

Amit Sharma (A)

Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, India choice.amit@gmail.com ashishbaldi@gmail.com.
Department of Pharmacy, Uttarakhand Technical University, Dehradun, Uttarakhand, India.

Ashish Baldi (A)

Department of Pharmaceutical Science and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India choice.amit@gmail.com ashishbaldi@gmail.com.

Dinesh Kumar Sharma (DK)

Department of Pharmaceutics, Himalayan Institute of Pharmacy & Research, Dehradun, Uttarakhand, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH